US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Ga

Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile

Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE)

-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule

drugs that address oncological and inflammatory diseases, today announced that its lead drug candidate Namodenoson was granted a patent

for its use as an anti-obesity drug by the US patent office. Namodenoson is currently being developed for the treatment of Metabolic

Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted,

Namodenoson had a very favorable safety profile when administered orally.

patent application No. 17/309,952 entitled "An A3 adenosine receptor ligand for use for achieving a fat loss effect", has

been accepted by the US Patent Office, will be issued on February 2nd and expires in 2042.

patent application covers methods of treating obese patients by administering Namodenoson in an oral formulation. Can-Fite has already

multiple approved patents and corresponding applications in a variety of territories around the world, for different clinical applications

anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the

increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental

animal model of obesity, induced by high fat diet. In a MASH Phase IIa study, in patients treated with Namodenoson, a 2.3% weight loss

has been observed after 3 months with a significant increase in serum adiponectin levels.

are delighted that the product protection of Namodenoson in the area of obesity has been accepted in the US and will be valid till 2042.

Namodenoson is currently being developed for the treatment of MASH in a Phase IIb study where most patients are obese. We look forward

to seeing the anti-obesity effect in this clinical study", said Motti Farbstein, Can-Fite CE&CFO.

obesity treatment industry worldwide is expected to reach a projected revenue of US$ 60.5 billion by 2030. A compound annual growth rate

of 22.3% is expected of the worldwide obesity treatment industry from 2025 2030.

is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is

currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated

Steatohepatitis (MASH), and in a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression

is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile

Can-Fite BioPharma Ltd.

BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that

is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug

candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase

III. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial

for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the

U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has

also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug

candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience

in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.

press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other

things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements

in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements

can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan,"

"may," "should" or "anticipate" or their negatives or other variations of these words or other comparable

words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate

to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate

to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors

that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance

or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance

or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history

of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms,

or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our

preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into

clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product

candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance

of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation

of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and

maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing

the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of

the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE

American; and statements as to the impact of the political and security situation in Israel on our business. More information on these

risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual

Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with

the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak

only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as

a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.